Zegfrovy

Pharma

FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy

Dizal has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only oral treatment for those with a rare type of NSCLC.

Kevin Dunleavy Jul 7, 2025 11:28am